Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Gland and Hormone Related Diseases

Uterine Cervical Neoplasms

Premature Birth

Primary Ovarian Insufficiency

Menopause, Premature

Menopause

All Drugs and Chemicals

Reproductive Control Agents

Antineoplastic Agents

Estradiol

Estrogens

Estradiol 17 beta-cypionate

Estradiol 3-benzoate

Polyestradiol phosphate

Testosterone

Methyltestosterone

Testosterone undecanoate

Testosterone enanthate

Testosterone 17 beta-cypionate

Androgens

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Anabolic Androgenic Steroids

Anabolic Agents

Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)

Subdermal implant-bioabsorbable placebo pellet (cholesterol)

Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)

testosterone pellet (100 mg)

Placebo

André Malavasi, PhD

Edmund Baracat, PhD

Estrogen and androgen deficiencies negatively impact the quality of life of women at different stages of life, especially after menopause. New modalities and new therapeutic alternatives have been researched. Parenteral administration of estradiol and testosterone could be effective to treat symptoms secondary to estrogen and androgen deficiencies and minimize these adverse events. This study evaluates the efficiency of subdermal implant-bioabsorbable use in women with menopausal symptoms associated with secondary estrogen and androgen deficiencies in women with natural menopause, premature ovarian failure or surgical menopause due to cervical cancer. Pharmacokinetic, biochemical, metabolic, thromboembolic and hormonal data will be evaluated, as well as the effects on quality of life, menopausal symptoms and sexual function after treatment.

The clinical study will be carried out on 140 women, who will be divided into three groups: (1) postmenopausal women with menopausal and sexual symptoms (n=60); (2) women with premature ovarian failure (n=40); (3) women with cervical cancer undergoing abdominal hysterectomy with bilateral adnexectomy, with menopausal and sexual symptoms (n=40).

All participants will answer questionnaires to assess quality of life, menopausal symptoms and sexual function. All participants will undergo general physical and gynecological examinations, as well as hormonal, biochemical, thromboembolic and imaging tests.

The study will last six months. The included participants will undergo the following visits: inclusion (post-selection) and 1, 3 and 6 months after implant insertion. For the pharmacokinetic study, blood samples will be collected at the following periods: inclusion (before implant placement) and after 1h, 2h, 3h, 6h and 12h; one week, two weeks and one month after placement, and then monthly until six months after implant insertion, to evaluate serum levels of Luteinizing hormone, Follicle stimulating hormone, estradiol, estrone, total testosterone and sex hormone-binding globulin.

Clinical, biochemical, hormonal and therapeutic parameters will be evaluated before placement (inclusion) and after 3 and 6 months. The Mann Whitney test will be applied to evaluate differences between measurements and the chi-square test will be applied to analyze the proportions of improvement between groups before and after treatment.

Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)

Pharmacokinetic, Clinical, Hormonal and Therapeutic Effects of the Use of Estradiol and Testosterone Hormonal Subdermal Implants in Women With Natural Menopause, Premature Ovarian Failure or Surgical Menopause Due to Cervical Cancer.

evaluate concentration in serum of luteinizing hormone, follicle stimulating hormone, estradiol, estrone, total testosterone and sex hormone-binding globulin.

Evaluate response on vulvovaginal atrophy and genitourinary syndrome of menopause, hormonal and metabolic effects on climacteric symptoms, using the Kupperman Menopausal Index; response in quality of life and sexual function; hormonal and metabolic effects;

University of Sao Paulo General Hospital

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)	NCT06343870	Menopause Testosterone De... Estrogen Defici...	testosterone pe... Placebo	18 Years - 60 Years	University of Sao Paulo General Hospital
Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)	NCT06343870	Menopause Testosterone De... Estrogen Defici...	testosterone pe... Placebo	18 Years - 60 Years	University of Sao Paulo General Hospital

Spots Global Cancer Trial Database for testosterone pellet (100 mg)